BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giovannini C, Fornari F, Indio V, Trerè D, Renzulli M, Vasuri F, Cescon M, Ravaioli M, Perrucci A, Astolfi A, Piscaglia F, Gramantieri L. Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2674. [PMID: 32961688 DOI: 10.3390/cancers12092674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Huang K, Wang P, Chuang C, Yong C, Liu Y, Huang P, Yao C, Lin Y, Tsai M. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma. Medicina 2022;58:259. [DOI: 10.3390/medicina58020259] [Reference Citation Analysis]
2 Yahya G, Hashem Mohamed N, Pijuan J, Seleem NM, Mosbah R, Hess S, Abdelmoaty AA, Almeer R, Abdel-Daim MM, Shulaywih Alshaman H, Juraiby I, Metwally K, Storchova Z. Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast. Microb Biotechnol 2021. [PMID: 34378349 DOI: 10.1111/1751-7915.13904] [Reference Citation Analysis]
3 Reungoat E, Grigorov B, Zoulim F, Pécheur EI. Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. Cancers (Basel) 2021;13:2270. [PMID: 34065048 DOI: 10.3390/cancers13092270] [Reference Citation Analysis]
4 Lee HW, Han DH, Shin HJ, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. Cancers (Basel) 2020;12:E3414. [PMID: 33217965 DOI: 10.3390/cancers12113414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]